OmniAb Inc (NAS:OABI)

Q2 2026 OmniAb Inc Earnings Call Transcript

Aug 6, 2026 / 08:30 PM GMT

Release Date Price: $2.24 (+10.34%)

Transcript 8-K

Key Points

Positve

OmniAb Inc (OABI) reported a strong second quarter with total revenue of $13.4 million, a significant increase from $3.9 million in the same period last year, driven by higher milestone revenue.
The company's partner portfolio has advanced significantly, with two programs (rimantomib and persentabartosentican) jumping from Phase 1 directly into Phase 3 during Q2, highlighting the potential of its technology.
OmniAb Inc (OABI) is the only company in the world with a transgenic chicken platform that creates fully human antibody sequences, providing a unique competitive advantage for targeting conserved or difficult-to-drug targets.
The company is seeing increasing partner interest and signed new agreements with Argenx and Rosa Therapeutics, indicating strong demand for its OmniChicken and OmniDab platforms.
OmniAb Inc (OABI) improved its net loss to $5.9 million in Q2 2026, compared to a net loss of $15.9 million in the year-ago period, and raised its full-year 2026 revenue guidance to $32 million-$36 million.
The company's cash position grew to $52 million in Q2, and it expects to end 2026 with $37 million-$41 million in cash, reflecting improved financial management and operational efficiencies.
OmniAb Inc (OABI) is seeing strong adoption of its Omni Ultra technology, which opens new markets for ultra-long CDRH3 antibodies and peptides, driving inbound interest and potential new applications.
The company's exploration platform is gaining traction with the sale of two instruments in Q2, and management believes it can become a meaningful complement to the antibody business with durable revenue streams.
OmniAb Inc (OABI) is well-positioned to benefit from AI and machine learning trends, leveraging its OmniDeep suite and exploration platform to generate proprietary data for novel target discovery.

Negative

OmniAb Inc (OABI)'s revenue is heavily dependent on milestone payments, which can vary significantly from quarter to quarter, making financial results lumpy and less predictable.
The company still faces a significant gap between its operating expenses and revenue, with expected 2026 GAAP operating expenses of $84 million-$88 million versus revenue of $32 million-$36 million.
OmniAb Inc (OABI) continues to operate at a net loss, with a year-to-date net loss of $13.6 million, and relies on future milestones and royalties to close the funding gap.
The exploration platform's revenue contribution is still early-stage, with only four instruments in the field, and management notes it is too early to discuss consumables or consistent sales cadence.
The company's cash runway, while improved, is still limited, and it may need to seek external funding if milestone payments or partner progress do not materialize as expected.
OmniAb Inc (OABI) faces potential delays in partner programs, as seen with the need for additional preclinical work for certain antibody programs, which could slow the progression of its pipeline.
The company's revenue guidance for the back half of 2026 implies lower quarterly revenue, reflecting the front-end loading of milestone achievements and potential conservatism in guidance.
OmniAb Inc (OABI) is still in a period where royalties are not yet a significant revenue stream, and the transition to royalty-based income depends on partner programs advancing to potential approvals.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

OABI.OQ - OmniAB Inc
Q2 2026 OmniAb Inc Earnings Call
Aug 06, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
There are now six programs in phase one or phase two clinical trials that are derived from our novel genetically engineered chicken antibody discovery technologies, specifically OmniDab and OmniChicken. I think it's worth noting that OmniAb is the only company in the world with a transgenic chicken platform that creates fully human antibody sequences.

Traditionally, many therapeutic targets are highly conserved or similar in sequence among mammals. And that adds to the value proposition of our transgenic chickens.

Part of the advantage of a chicken platform is based on the evolutionary distance of a chicken as a biological host for discovery versus other animals, specifically mammals. So this distance allows our chickens to create a

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.